# US 2013/0158374 A1 · System for Glycated Protein Detection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158374 A1
- Document ID: US20130158374A1
- Status: Published application
- Kind: A1
- Application number: 13/407,842
- Filed: 2012-02-29
- Published: 2013-06-20
- Earliest claimed: 2008-07-01
- Assignees: Veritide Limited
- Inventors: Lou Reinisch
- Web page: https://patentgrep.com/patent/US20130158374A1

## CPC

- A61B 5/0071: {by measuring fluorescence emission}
- C12M 1/3476: {Fluorescence spectroscopy}
- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- G01N 21/85: Investigating moving fluids or granular solids
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/48: Biological material, e.g. blood, urine (G01N33/02, G01N33/26, G01N33/44, G01N33/46 take precedence); Haemocytometers (counting blood corpuscules distributed over a surface by scanning the surface G06M11/02)
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N 2800/042: Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- C12M: APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; {APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method of detecting the presence of glycated proteins or peptides (GPs) in a sample comprises carrying out the steps of assessing the sample for fluorescence, subjecting the sample to UV radiation, and reassessing the sample for an increase in fluorescence relative to any fluorescence assessed in said first assessing step, an increase in fluorescence at said reassessing step being indicative of the presence of GPs. The method may be useful for detecting disease such as diabetes.

## Claims

### Claim 1

A method of detecting the presence of glycated proteins or peptides in a sample comprising carrying out the steps of assessing the sample for fluorescence, subjecting the sample to UV radiation, and reassessing the sample for an increase in fluorescence relative to any fluorescence assessed in said first assessing step, the presence of fluorescence at said assessing step and an increase in fluorescence at said reassessing step being indicative of the presence of glycated proteins or peptides.

### Claim 2 (depends on 1)

A method according to claim 1 including subjecting the sample between assessments to UV radiation in the wavelength range 200-300 nm.

### Claim 3 (depends on 1)

A method according to claim 1 including subjecting the sample between assessments to UV radiation in the wavelength range 250-260 nm.

### Claim 4 (depends on 1)

A method according to claim 1 including subjecting the sample between assessments to UV radiation of about 254 nm wavelength.

### Claim 5 (depends on 1)

A method according to claim 1 including subjecting the sample to UV radiation between assessments for less than 5 minutes.

### Claim 6 (depends on 1)

A method according to claim 1 including measuring actual fluorescence of the sample in said assessment steps.

### Claim 7 (depends on 6)

A method according to claim 6 including measuring any change in actual fluorescence between the assessment and the reassessment steps.

### Claim 8 (depends on 1)

A method according to claim 1 comprising assessing and reassessing the fluorescence of the sample by reference to substantially only horizontally polarised fluorescent light.

### Claim 9 (depends on 8)

A method according to claim 8 including causing the fluorescence to pass a filter oriented to pass substantially only horizontally polarised light.

### Claim 10 (depends on 9)

A method according to claim 9 including in the assessment and reassessment steps exposing the sample to vertically polarised light as the excitation light.

### Claim 11 (depends on 1)

A method according to claim 1 including spectrally resolving the fluorescence observed in the assessment and reassessment steps.

### Claim 12 (depends on 11)

A method according to claim 11 including spectrally resolving the fluorescence observed in the assessment and reassessment steps and analysing the shape of the fluorescence.

### Claim 13 (depends on 1)

A method according to claim 1 including assessing the fluorescence of the sample, subjecting the sample to a pulse of UV radiation, and reassessing the fluorescence of the sample after a delay.

### Claim 14 (depends on 13)

A method according to claim 13 including reassessing the fluorescence of the sample after a period of time substantially corresponding to the fluorescence lifetime of a class of glycated proteins or peptides.

### Claim 15 (depends on 1)

A method according to claim 1 including assessing the fluorescence of the sample, subjecting the sample to a modulated UV signal, and reassessing the fluorescence of the sample for a modulated response.

### Claim 16 (depends on 1)

A method according to claim 1 wherein the sample is a portion of skin of a living person or animal or a sample from a living person or animal.

### Claim 17 (depends on 1)

A method according to claim 1 wherein the sample is of or from a person and including assessing the sample for the presence of glycated proteins or peptides as indicative of the presence of a disease in the person.

### Claim 18

A detector for detecting for the presence of glycated proteins or peptides in a sample comprising a UV source, a detection zone within which the sample may be placed or may pass, means for fluorescence analysis arranged to assess for the presence of glycated proteins or peptides by assessing the sample for fluorescence, subjecting the sample to UV radiation, and then reassessing the sample for an increase in fluorescence relative to any fluorescence assessed in said first assessing step, the presence of fluorescence at said assessing step and an increase in fluorescence at said reassessing step being indicative of the presence of glycated proteins or peptides.

### Claim 19 (depends on 18)

A detector according to claim 18 wherein said source or sources of UV radiation is or are operable to irradiate the sample with UV radiation having a wavelength in the range of 200-300 nm as the radiation having the wavelength effective to cause fluorescence of the sample.

### Claim 20 (depends on 18)

A detector according to claim 18 wherein said source or sources of UV radiation is or are operable to irradiate the sample with UV radiation having a wavelength of about 254 nm wavelength as the radiation having the wavelength effective to cause fluorescence of the sample.

### Claim 21 (depends on 18)

A detector according to claim 18 wherein said radiation detector is arranged to detect substantially only horizontally polarized fluorescent radiation.

### Claim 22 (depends on 18)

A detector according to claim 18 wherein said source or sources of UV radiation include a source of UV radiation operable to irradiate the sample with vertically polarized UV radiation as the radiation having the wavelength effective to cause fluorescence of the sample.

### Claim 23 (depends on 22)

A detector according to claim 22 wherein said source or sources of UV radiation include a source of UV radiation operable to irradiate the sample with vertically polarized UV radiation as the radiation having the wavelength effective to cause fluorescence of the sample.

### Claim 24 (depends on 18)

A detector according to claim 18 wherein said computer apparatus is arranged to spectrally resolve the first and second florescence signals.

### Claim 25 (depends on 18)

A detector according to claim 18 wherein said computer apparatus is arranged to spectrally resolve the first and second fluorescence signals and analyse the shape of the fluorescence signals.

### Claim 26 (depends on 18)

A detector according to claim 18 wherein said source or sources of UV radiation include a source of UV radiation operable to irradiate the sample with UV radiation having a wavelength effective to cause a photochemical change in the sample as a pulse of said UV radiation, and wherein said computer apparatus is arranged to record said second fluorescence signal after a time period from the end of said pulse of between 0.1-10 ns.

### Claim 27 (depends on 18)

A detector according to claim 18 wherein said source or sources of UV radiation is or are operable to irradiate the sample with modulated UV radiation, and said radiation detector is arranged to detect a modulated fluorescence response.

### Claim 28

Apparatus for detecting glycated proteins or peptides in a sample comprising:
a source or sources of UV radiation disposed for irradiating a sample and operable to irradiate the sample with UV radiation having a wavelength effective to cause fluorescence of the sample and subsequently with UV radiation having a wavelength effective to cause a photochemical change in the sample;
a radiation detector disposed for receiving fluorescence radiation from the sample when irradiated by said source or sources of UV radiation and generating a fluorescence signal upon receiving said fluorescence radiation; and
a computer apparatus operatively connected to said radiation detector or detectors and programmed to (a) record a first fluorescence signal from said radiation detector after the sample is first irradiated with UV radiation having a wavelength effective to cause fluorescence of the sample; (b) record a second fluorescence signal from said radiation detector after the sample is irradiated with UV radiation having a wavelength effective to cause a photochemical change in the sample and then re-irradiated with UV radiation having a wavelength effective to cause fluorescence of the sample; (c) compare said first and second fluorescence signals; and then (d) determine if there is any enhancement of the fluorescence of the sample to thereby detect the presence of glycated proteins or peptides.

### Claim 29 (depends on 28)

An apparatus according to claim 28 wherein said source or sources of UV radiation comprise(s) first and second sources of UV radiation wherein the first source is operable to irradiate the sample with UV radiation having the wavelength effective to cause fluorescence of the sample and the second source is operable to irradiate the sample with UV radiation having the wavelength effective to cause a photochemical change in the sample, and
said radiation detector comprises first and second radiation detectors wherein the first radiation detector is disposed for receiving the fluorescence radiation from the sample when irradiated by the first source UV radiation and generating the first fluorescence signal upon receiving said fluorescence radiation and the second radiation detector is disposed for receiving fluorescence radiation from the sample when re-irradiated by the second source of UV radiation and generating the second fluorescence signal upon receiving said fluorescence radiation.

### Claim 30

A method of diagnosing diabetes in a person or a likelihood of a person becoming diabetic, which comprises assessing the skin or a blood sample of the person for fluorescence, subjecting the skin or blood sample to UV radiation, and reassessing the skin or blood sample for an increase in fluorescence relative to any fluorescence assessed in said first assessing step, the presence of fluorescence at said assessing step and an increase in fluorescence at said reassessing step being indicative of the presence of diabetes or likelihood of the person becoming diabetic.

### Claim 31 (depends on 17)

A method according to claim 17 wherein the disease is selected from any one or more of retinal dysfunction, cardiovascular disease, obesity, metabolic syndrome, diabetes, neurodegenerative disease, cancer, and renal disease.

### Claim 32 (depends on 31)

A method according to claim 31 wherein the disease is diabetes.
